Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Work
Year: 2022
Type: article
Abstract: The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolid... more
Source: Journal of Clinical Oncology
Institutions Tennessee Oncology, Sarah Cannon, The Christie NHS Foundation Trust, University of Manchester, Moffitt Cancer Center +29 more
Cites: 24
Cited by: 836
Related to: 10
FWCI: 184.1
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: hybrid